126 related articles for article (PubMed ID: 2714342)
1. Phase II study of tauromustine in disseminated malignant melanoma.
Nolte H; Gjedde SB; Lindegaard-Madsen E; Bergh J; Blomquist E; Mouridsen HT
Eur J Cancer Clin Oncol; 1989 Apr; 25(4):655-7. PubMed ID: 2714342
[TBL] [Abstract][Full Text] [Related]
2. TCNU (LS 2667), a new active drug in the treatment of advanced colorectal cancer. EORTC Early Clinical Trials Group.
Gundersen S; Dombernowsky P; Cavalli F; Bruntsch U; Renard J; Van Glabbeke M; Pinedo H
Eur J Cancer Clin Oncol; 1989 Jul; 25(7):1095-7. PubMed ID: 2759163
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of TCNU, a novel nitrosourea.
Smyth JF; Macpherson JS; Warrington PS; Kerr ME; Whelan JM; Cornbleet MA; Leonard RC
Eur J Cancer Clin Oncol; 1987 Dec; 23(12):1845-9. PubMed ID: 3436348
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase II trial of TCNU versus mitozolomide in malignant melanoma. EORTC Early Clinical Trials Group.
Smyth JF; Gundersen S; Renard J; Pinedo HM
Eur J Cancer Clin Oncol; 1989 Apr; 25(4):755-7. PubMed ID: 2714350
[No Abstract] [Full Text] [Related]
5. Phase I study of tauromustine administered in a weekly schedule.
Gjedde SB; Mouridsen HT; L-Madsen E; Jensen NV; Blomquist E; Bergh J; Söderberg M; Wählby S
Eur J Cancer; 1993; 29A(13):1901-2. PubMed ID: 8260251
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy with tauromustine in advanced non-small cell lung cancer. A trial of the Phase II Study Group of the Association for Medical Oncology of the German Cancer Society.
Gatzemeier U; Drings P; Edler L; Fiebig HH; Hinke A; Rieche K; Tessen HW
Onkologie; 1990 Jun; 13(3):186-8. PubMed ID: 2168534
[TBL] [Abstract][Full Text] [Related]
7. A phase I clinical evaluation of 1-(2-chloroethyl)-3-[2-(dimethylaminosulphonyl)ethyl]-1-nitrosou rea (TCNU).
Vibe-Petersen J; Bork E; Møller H; Hansen HH
Eur J Cancer Clin Oncol; 1987 Dec; 23(12):1837-43. PubMed ID: 3436347
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of tauromustine in disseminated malignant melanoma.
Gjedde SB; Mouridsen HT; L-Madsen E; Jensen NV; Blomquist E; Bergh J; Söderberg M; Wählby S
Eur J Cancer; 1994; 30A(4):566. PubMed ID: 8018421
[No Abstract] [Full Text] [Related]
9. TCNU in adenocarcinoma of the lung: a phase II study with divided doses.
Sørensen JB; Bach F; Dombernowsky P; Vibe-Petersen J; Hansen HH
Ann Oncol; 1990 Jul; 1(4):299-300. PubMed ID: 2265139
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of tauromustine in malignant glioma.
Gregor A; Rampling R; Aapro M; Malmström P; Whittle IR; Rye R; Stewart M; Sellar R; Demierre B; Ironside JW
Eur J Cancer; 1992; 28A(12):1959-62. PubMed ID: 1419289
[TBL] [Abstract][Full Text] [Related]
11. Two phase III trials of tauromustine (TCNU) in advanced colorectal cancer.
Smyth JF; Hardcastle JD; Denton G; Alderson D; Grace RH; Mansi JL; Yosef HM; Nordle O; Lauri H; Wählby S
Ann Oncol; 1995 Nov; 6(9):948-9. PubMed ID: 8624301
[No Abstract] [Full Text] [Related]
12. A phase II trial of TCNU in patients with squamous, adeno and large cell carcinoma of the lung.
Vibe-Petersen J; Bach F; Pedersen AG; Smyth J; Hansen HH
Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1881-5. PubMed ID: 2561100
[No Abstract] [Full Text] [Related]
13. TCNU in advanced renal cancer. Phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group.
Van Oosterom AT; Droz JP; Fossa ST; Bono AV; Splinter TA; Verbaeys AJ; Keizer J; De Pauw M; Sylvester R
Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1889-90. PubMed ID: 2632270
[No Abstract] [Full Text] [Related]
14. Phase II trial of PCNU in advanced malignant melanoma: an Eastern Cooperative Oncology Group pilot study.
Earhart RH; Muggia FM; Golomb FM
Invest New Drugs; 1985; 3(3):297-301. PubMed ID: 4066223
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma.
Jacquillat C; Khayat D; Banzet P; Weil M; Avril MF; Fumoleau P; Namer M; Bonneterre J; Kerbrat P; Bonerandi JJ
Cancer Chemother Pharmacol; 1990; 25(4):263-6. PubMed ID: 2403853
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of tauromustine in cancer patients. Phase I studies.
Gunnarsson PO; Vibe-Petersen J; Macpherson JS; Warrington PS; Polacek J; Ellman M; Hansen HH; Smyth JF
Cancer Chemother Pharmacol; 1989; 23(3):176-80. PubMed ID: 2924375
[TBL] [Abstract][Full Text] [Related]
17. Second-line chemotherapy of disseminated malignant melanoma with cystemustine at 60 mg/m2: a phase II trial.
Thivat E; Durando X; D'Incan M; Cure H; Mouret-Reynier MA; Madelmont JC; Souteyrand P; Chollet P
Anticancer Drugs; 2005 Oct; 16(9):1003-7. PubMed ID: 16162977
[TBL] [Abstract][Full Text] [Related]
18. Interim report of phase II study of new nitrosourea S 10036 in disseminated malignant melanoma.
Khayat D; Bizzari JP; Frenay M; Naman H; Weil M; Goupil A; Namer M; Rouesse J; Banzet P; Jacquillat C
J Natl Cancer Inst; 1988 Nov; 80(17):1407-8. PubMed ID: 3172267
[TBL] [Abstract][Full Text] [Related]
19. Fotemustine in the treatment of brain primary tumors and metastases.
Khayat D; Giroux B; Berille J; Cour V; Gerard B; Sarkany M; Bertrand P; Bizzari JP
Cancer Invest; 1994; 12(4):414-20. PubMed ID: 8032964
[TBL] [Abstract][Full Text] [Related]
20. Second-line chemotherapy with tauromustine in metastatic breast cancer in postmenopausal women: a phase II study.
Ernst P; Balslev I; Mouridsen HT
Cancer Treat Rep; 1987 Oct; 71(10):987-8. PubMed ID: 3652062
[No Abstract] [Full Text] [Related]
[Next] [New Search]
